Study of NTBC for Tyrosinemia I

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

1998-10-31

Study Completion Date

2006-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

OBJECTIVES: I. Assess the safety and efficacy of NTBC in children with tyrosinemia I.

II. Evaluate the effects of NTBC on survival, rate of neurologic crises, improvement in renal tubular damage, reduction in the need for liver transplantation, and reduction in the development of hepatocarcinoma in these patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Antithyroid Drug Treatment of Thyrotoxicosis in Young People

NCT01436994

Paediatric Thyrotoxicosis

COMPLETED PHASE3

Thyroxine Replacement in Organ Donors

NCT00238030

Brain Death

COMPLETED PHASE1/PHASE2

Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH)

NCT05228184

Congenital Hypothyroidism

TERMINATED PHASE4

Levothyroxine for Children With Euthyroid Sick Syndrome

NCT01631305

Euthyroid Sick Syndrome

COMPLETED PHASE4

Supplemental Thyroxine Treatment for Preterm Infants With Hypothyroxinemia

NCT00565890

Hypothyroxinemia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PROTOCOL OUTLINE: Patients are stratified according to age at onset of symptoms (0-2 months vs 2-6 months vs greater than 6 months).

Patients receive oral NTBC twice a day. Treatment continues in the absence of unacceptable toxicity.

Patients are followed once a month for 6 months, then every 3 months thereafter.

Completion date provided represents the completion date of the grant per OOPD records

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tyrosinemia I

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NTBC

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed diagnosis of tyrosinemia Detected through newborn screening before the onset of symptoms OR Diagnosed on the basis of symptoms (liver disease, neurological crises, growth failure) and succinylacetone in urine or blood and/or fumarylacetoacetate dehydratase deficiency in cultured fibroblasts or liver biopsy

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No